Cargando…
333. Tedizolid Activity against Gram-Positive Bacterial Isolates Causing Bone and Joint Infections in the United States (2015–2019)
BACKGROUND: Prolonged systemic antibiotic courses are frequently used to manage difficult-to-treat bone and joint infections (BJI). Tedizolid has been considered as a therapy candidate for BJI in adults and children. This study assessed the in vitro activity of tedizolid and comparator agents agains...
Autores principales: | Carvalhaes, Cecilia G, Sader, Helio S, Streit, Jennifer M, Castanheira, Mariana, Mendes, Rodrigo E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776679/ http://dx.doi.org/10.1093/ofid/ofaa439.529 |
Ejemplares similares
-
1547. Activity of Tedizolid and Comparator Agents against Gram-Positive Bacterial Isolates Causing Skin and Skin Structure Infections in Pediatric Patients during 2015-2019 in the US
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020) -
Five-year analysis of the in vitro activity of tedizolid against a worldwide collection of indicated species causing clinical infections: results from the Surveillance of Tedizolid Activity and Resistance (STAR) programme
por: Carvalhaes, Cecilia G, et al.
Publicado: (2022) -
Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010–2019)
por: Carvalhaes, Cecilia G., et al.
Publicado: (2022) -
Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Nosocomial- and Community-Acquired Infections in United States Hospitals (2014–2016)
por: Mendes, Rodrigo E, et al.
Publicado: (2017) -
129. Antimicrobial Activity of Ceftazidime–avibactam and Comparator Agents Tested against Gram-Negative Organisms Isolated from Patients with Bloodstream Infections in United States Medical Centers (2017–2018)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2019)